NeoGenomics, Inc. revised earnings guidance for the full year ending December 31, 2023. For the year, the company expected consolidated revenue to be in the range of $585 million to $592 million against the previous guidance range of $565 million to $575 million. Net loss to be in the range of $95 million to $89 million against the previous guidance range of $107 million to $100 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.63 USD | -0.89% | +0.77% | -3.40% |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.40% | 2.01B | |
-15.12% | 8.49B | |
+60.25% | 4.08B | |
-43.01% | 2.42B | |
-9.98% | 2.42B | |
-3.24% | 2.33B | |
-19.79% | 1.53B | |
-40.57% | 1.26B | |
+9.11% | 1.07B | |
+13.28% | 985M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023